Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077623 · ClinicalTrials.gov registry record · Phase 3
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 572
- Enrollment target
NCT00077623 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 572 participants.
The verdict
NCT00077623, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 572 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
Interventions
- DRUG epoetin alfa or beta
- DRUG methoxy polyethylene glycol-epoetin beta (Mircera)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077623
The ClinicalTrials.gov registry entry for NCT00077623 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which epoetin alfa or beta is the first listed.
NCT00077623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077623 about?
NCT00077623 is a clinical study titled "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.". This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-...
What is the current status of trial NCT00077623?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 572 participants. The study started on 2004-03. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00077623?
The interventions under investigation include: epoetin alfa or beta (DRUG), methoxy polyethylene glycol-epoetin beta (Mircera) (DRUG).
Who is sponsoring clinical trial NCT00077623?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.